In the BioHarmony Drug Report Database

"Preview" Icon

Fondaparinux

Arixtra (fondaparinux) is an oligosaccharide pharmaceutical. Fondaparinux was first approved as Arixtra on 2001-12-07. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat myocardial infarction, pulmonary embolism, unstable angina, and venous thrombosis. The pharmaceutical is active against antithrombin-III.

 

Trade Name

 

Arixtra
 

Common Name

 

fondaparinux
 

ChEMBL ID

 

CHEMBL1201202
 

Indication

 

myocardial infarction, pulmonary embolism, unstable angina, venous thrombosis
 

Drug Class

 

Antithrombotyic indirect selective synthetic factor Xa inhibitors

Image (chem structure or protein)

Fondaparinux structure rendering